Catalyst Biosciences Inc (NASDAQ:CBIO) saw strong trading volume on Wednesday . 1,348,338 shares traded hands during trading, an increase of 191% from the previous session’s volume of 463,862 shares.The stock last traded at $12.91 and had previously closed at $9.96.
Several equities analysts have recently commented on the stock. B. Riley assumed coverage on shares of Catalyst Biosciences in a research note on Friday, December 8th. They set a “buy” rating and a $19.00 price objective for the company. Zacks Investment Research raised shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Wednesday, November 8th.
A number of hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its stake in Catalyst Biosciences by 117.0% in the third quarter. Dimensional Fund Advisors LP now owns 173,555 shares of the biopharmaceutical company’s stock worth $873,000 after buying an additional 93,592 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Catalyst Biosciences by 294.1% during the second quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 32,621 shares in the last quarter. Zacks Investment Management bought a new position in shares of Catalyst Biosciences during the second quarter valued at approximately $147,000. Bank of New York Mellon Corp bought a new position in shares of Catalyst Biosciences during the second quarter valued at approximately $107,000. Finally, Virtu KCG Holdings LLC bought a new position in shares of Catalyst Biosciences during the second quarter valued at approximately $103,000. 30.96% of the stock is owned by institutional investors.
WARNING: “Catalyst Biosciences (CBIO) Sees Large Volume Increase” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/12/20/catalyst-biosciences-cbio-sees-large-volume-increase.html.
About Catalyst Biosciences
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.